Patents matching “formulation”

US 8778398

Immediate release formulations and dosage forms of gamma-hydroxybutyrate

Jazz Pharmaceuticals, Inc. · Granted Jul 15, 2014 · Expires Jul 10, 2034

US 8771648

(Trimethoxyphenylamino) pyrimidinyl formulations

Rigel Pharmaceuticals, Inc. · Granted Jul 8, 2014 · Expires Jul 3, 2034

US 8765665

Albumin-free factor VIII formulations

UNIVERSITY OF CONNECTICUT · Granted Jul 1, 2014 · Expires Jun 26, 2034

US 8765717

Meloxicam and glucosamine formulation and uses thereof

Monte Verde S.A. · Granted Jul 1, 2014 · Expires Jun 26, 2034

US 8765171

Methods and compositions for liposomal formulation of antigens and uses thereof

The Regents of the University of California · Granted Jul 1, 2014 · Expires Jun 26, 2034

US 8758813

Abuse-deterrent drug formulations

Collegium Pharmaceutical, Inc. · Granted Jun 24, 2014 · Expires Jun 19, 2034

US 8748472

Stabilized formulations of CNS compounds

Supernus Pharmaceuticals, Inc. · Granted Jun 10, 2014 · Expires Jun 5, 2034

US 8748573

Formulations comprising linaclotide

IRONWOOD PHARMACEUTICALS, INC. · Granted Jun 10, 2014 · Expires Jun 5, 2034

US 8722645

Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

GALECTIN THERAPEUTICS, INC. · Granted May 13, 2014 · Expires May 8, 2034

US 8709478

Once daily formulations of tetracyclines

Supernus Pharmaceuticals, Inc. · Granted Apr 29, 2014 · Expires Apr 24, 2034

US 8710004

Stable liquid VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. · Granted Apr 29, 2014 · Expires Apr 24, 2034

US 8703727

Nanotechnology formulation of poorly soluble compounds

Aphios Corporation · Granted Apr 22, 2014 · Expires Apr 17, 2034

US 8697644

Stable formulations for parenteral injection of peptide drugs

XERIS PHARMACEUTICALS, INC. · Granted Apr 15, 2014 · Expires Apr 10, 2034

AU 2012308663

Formulations of cyclopropanecarboxylic acid {2-[1S)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware

CELGENE CORP [CH] · Granted Apr 3, 2014 · Expires Mar 29, 2034

US 8679557

Synergistic herbal ophthalmic formulation for lowering the intra ocular pressure in case of glaucoma

SENTISS PHARMA PRIVATE LIMITED · Granted Mar 25, 2014 · Expires Mar 20, 2034

US 8663683

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Mar 4, 2014 · Expires Feb 27, 2034

US 8653060

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Feb 18, 2014 · Expires Feb 13, 2034

US 8652516

Doxycycline formulations, and methods of treating rosacea

Cerovene, Inc. · Granted Feb 18, 2014 · Expires Feb 13, 2034

US 8642107

Water formulation with herbal hint and a process therefor

Century Biologicals Private Limited · Granted Feb 4, 2014 · Expires Jan 30, 2034

US 8642076

Lipid containing formulations

Tekmira Pharmaceuticals Corporation · Granted Feb 4, 2014 · Expires Jan 30, 2034

US 8633178

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Jan 21, 2014 · Expires Jan 16, 2034

US 8597616

Dry powder drug delivery formulations, methods of use, and devices therefore

The Board of Regents of the University of Texas System · Granted Dec 3, 2013 · Expires Nov 28, 2033

US 8574545

Labeled iodinated tropane formulation

Alseres Pharmaceuticals, Inc. · Granted Nov 5, 2013 · Expires Oct 31, 2033

US 8563593

Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide

Vertex Pharmaceuticals Incorporated · Granted Oct 22, 2013 · Expires Oct 17, 2033